

# A Post-Marketing Surveillance Study to Evaluate Performance of the EXIMO™ Blood Glucose Monitoring System

SONIA R. CHANDNANI<sup>1</sup>, C. D. RAMAKRISHNA<sup>2</sup>, BHARGAV A. DAVE<sup>3</sup>, PANKAJ S. KOTHAVADE<sup>4</sup>, ASHOK S THAKKAR<sup>5</sup>

## ABSTRACT

**Introduction:** The performance of Blood Glucose Monitoring System (BGMS) is critical as the information provided by the system guide the patient or health care professional in making treatment decisions. However, besides evaluating accuracy of the BGMS in laboratory setting, it is equally important that the intended users (healthcare professionals and patients) should be able to achieve blood glucose measurements with similar level of high accuracy.

**Aim:** To assess the performance of EXIMO™ (Meril Diagnostics Pvt. Ltd., Vapi, Gujarat, India) BGMS as per International Organization for Standardization (ISO) 15197:2013 section 8 user performance criteria.

**Materials and Methods:** This was a non-randomized and post-marketing study conducted at a tertiary care centre of India. A total of 1005 patients with diabetes themselves performed fingertip blood glucose measurement using EXIMO™ BGMS. Immediately after capillary blood glucose measurement using the blood glucose monitoring system, venous blood sample from each patient was obtained by a trained technician which

was assessed by reference laboratory method- Cobas Integra 400 plus (Roche Instrument Centre, Rotkreuz, Switzerland). All the blood glucose measurements assessed by EXIMO™ were compared with laboratory results. Performance of the system was assessed as per ISO 15197:2013 criteria using Bland-Altman plot, Parkes-Consensus Error Grid (CEG) and Surveillance Error Grid analyses (SEG).

**Results:** A total of 1005 patients participated in the study. Average age of the patients was 44.93±14.65 years. Evaluation of capillary fingertip blood glucose measurements demonstrated that 95.82% measurements fulfilled ISO 15197:2013 section 8 user performance criteria. All the results lie within clinically non-critical zones; Zone A (99.47%; n=1000) and Zone B (0.53%; n=05) of the CEG analysis. As per SEG analysis, majority of the results fell within “no-risk” zone (risk score 0 to 0.5; 90.42%).

**Conclusion:** The result of the study confirmed that intended users are able to obtain accurate glucose measurements when operating EXIMO™ BGMS, given only the instructions and training materials routinely provided with the system, in clinical practice.

**Keywords:** Consensus error grid, Diabetes mellitus, Glucose meter, Surveillance error grid

## INTRODUCTION

Self-monitoring of blood glucose is an integral component of comprehensive diabetes treatment regimen as it improves glycaemic control and reduces the risks for potential clinical complications associated with poor-glycaemic control [1-5]. Real-time data obtained through the use of the BGMS reflects the influence of physical activity and diet on blood-glucose levels and thereby motivate the patients for life-style modification [6]. Moreover, the blood glucose measurements also guide the treating physician to establish pattern of abnormal glucose levels in order to make changes in treatment regimen [7]. Hence, the use of the BGMS is widely accepted in clinical practice as a part of diabetes management [8].

As the information provided from these devices is used for making treatment decisions, the accuracy of the BGMS is prerequisite for the sustained success of diabetes treatment regimen. The accuracy of BGMS can be assessed based on the guidelines set forth by ISO 15197:2003 describes requirements of design, safety and analytical performance for BGMS. In view of advancement in technology and importance of BGMS in the treatment of diabetes, the guidelines were revised in 2013 with more stringent criteria (ISO 15197:2013). However, Klonoff and Prahald claim that only 32% (31/98) approved BGMS met analytical accuracy criteria of ISO 15197:2013 [9].

It should be noted that analytical performance evaluations provide standardized and reproducible information for measurement quality of the BGMS when the measurements are performed by well-trained laboratory personnel [10]. However, untrained users (patients) may

found difficulty in obtaining accurate results if the high-quality BGMS is difficult to handle or if the instructions for use are incomplete or unclear [10]. Hence, ISO 15197 requires user performance evaluation to confirm if intended users are able to achieve accurate measurement results with the BGMS (based upon instructions of use, without any training or assistance).

The EXIMO™ (Meril Diagnostics Pvt. Ltd., Vapi, Gujarat, India) is the BGMS which is intended for in vitro diagnostic use by diabetic patients or by healthcare professionals in a clinical environment. The EXIMO™, BGMS utilises test-strips that contains flavin adenine dinucleotide-glucose dehydrogenase (FAD-GDH) enzyme in combination with a proprietary electron mediators to measure fresh capillary or venous blood glucose levels [11]. The glucose range of EXIMO™ is 20-500 mg/dl. The objective of the present study was to assess performance of EXIMO™, as per ISO 15197:2013 section 8 user performance criteria.

## MATERIALS AND METHODS

This was a single center, non-randomized, post-marketing study. The study was conducted between September 2016 and November 2016 at Bombay Maternity and Surgical Hospital, Surat, Gujarat, India. The study enrolled patients of either sex, aged ≥18 years and diagnosed with diabetes mellitus. The clinical records of the patients were reviewed for confirmation of diabetes and comorbidities. Patients were excluded: 1) if they had haemophilia, bleeding disorder, or clotting problems; 2) if they had infections or skin disorders at the puncture site or any other condition which in

opinion of the investigator would put the participant or study at risk. Written informed consent was obtained from all the participants before the commencement of the study. The study was approved by Institutional Review Board.

Prior to blood testing, each study participant was provided user guide and quick reference guide to learn how to use the EXIMO™ BGMS. Participants were given adequate time to practice testing with BGMS. However, none of the patient received additional training to learn self-estimation of the blood glucose using the BGMS. The patients performed fingertip blood glucose measurement using the BGMS. After capillary blood glucose estimation with the BGMS, venous blood sample from each patient was obtained (within 5 minute) by a trained health care professional. Plasma glucose concentrations of these venous blood samples were determined by the Cobas Integra 400 plus (Roche Instrument Centre, Rotkreuz, Switzerland) which served as the reference values.

After blood glucose measurement, all the patients completed a questionnaire on the BGMS and instructions for use. Questionnaire was designed according to requirements of ISO 15197:2013(E) [12]. The questionnaire is enlisted below:

1. I find meter easy to use.
2. The instructions were easy to follow.
3. The test results displayed on the meter were easy to see.
4. It was easy to understand the test results.
5. The instructions clearly explain what to do if an error message is displayed on the glucose monitor.

Responses provided by the patients were scored on basis of Likert-type scale (strongly disagree (1) to strongly agree (5)).

## STATISTICAL ANALYSIS

The performance of the EXIMO™ BGMS was assessed as per ISO 15197:2013 section 8 criteria ( $\geq 95\%$  of results fall within  $\pm 15$  mg/dl of the reference results for sample blood glucose  $< 100$  mg/dl and  $\pm 15\%$  of the reference results for sample blood glucose  $\geq 100$  mg/dl). Bland-Altman plot was generated to display the difference between the BGMS results and the reference results [13]. The CEG analysis was performed to assess the clinical importance of the BGMS errors [14]. The analyses were performed using a Microsoft Excel™ VBA macro program (Microsoft Corporation, Redmond, WA, USA). We also performed SEG analyses, a novel error grid system introduced recently by several medical societies and authorities [15].

## RESULTS

A total of 1005 patients participated in the study. Average age of patients was  $44.93 \pm 14.65$  (Median 44 years; range 18-95 years). The demographic detail of the patients is summarized in [Table/Fig-1].

All the included patients performed fingertip puncture to measure capillary blood glucose level using the EXIMO™ system. The range of capillary blood glucose concentration as measured by the BGMS was 38 mg/dl to 482 mg/dl (median 97 mg/dl). Similarly, the range of venous blood glucose concentration as measured by reference method was 44 mg/dl to 500 mg/dl (median 96.9 mg/dl). Mean glucose levels measured by EXIMO™ and reference method were  $123.06 \pm 72.02$  mg/dl and  $125.37 \pm 73.35$  mg/dl, respectively. A total of 568 (57%) samples had glucose concentrations  $\leq 100$  mg/dl and the remaining 437 (43%) samples showed glucose concentrations  $> 100$  mg/dl.


Evaluation of capillary fingertip blood glucose measurements demonstrated that 95.82% measurements fulfilled ISO 15197:2013 section 8 criteria. [Table/Fig-2] depicts summary of blood glucose measurements as per ISO 15197:2013 section 8 criteria. Regression analysis demonstrated strong agreement between BGMS measurements and reference measurements ( $R^2=0.982$ )

Number of subjects	n=1005
Age, Mean $\pm$ SD	44.93 $\pm$ 14.65
Number of female, n (%)	551 (54.80%)
Number of male, n (%)	454 (45.20%)
Educational level	
Less than high school, n (%)	335 (33%)
High school, n (%)	171 (17%)
Some college or technical school, n (%)	131 (13%)
Graduate degree, n (%)	236 (24%)
Postgraduate degree, n (%)	132 (13%)


[Table/Fig-1]: Demographic characteristics of the study subjects.

Glucose concentration	Number of results within specified limits			
	$\pm 5$ mg/dl	$\pm 10$ mg/dl	$\pm 15$ mg/dl	$\pm 20$ mg/dl
$\leq 100$ mg/dl (n = 568)	257 (45.24%)	429 (75.52%)	545 (95.95%)	568 (100%)
$> 100$ mg/dl (n = 437)	245 (56.06%)	344 (78.71%)	418 (95.65%)	437 (100%)
Total (n = 1005)	502 (49.95%)	773 (76.91%)	963 (95.82%)	1005 (100%)

[Table/Fig-2]: Summary of BGMS results as per criteria of ISO 15197:2013 section 8.




[Table/Fig-3]: Linear regression analysis of EXIMO™ measurements versus laboratory reference measurements.




[Table/Fig-4]: Bland-Altman plot demonstrating difference of EXIMO™ measurements from reference measurements.

[Table/Fig-3]. The Bland-Altman plots of the difference of the BGMS measurements from reference measurements are shown in [Table/Fig-4]. The CEG analysis showed that 99.47% (n=1000) of the results fell in Zone-A and the remaining results (0.53%, n=05) fell in Zone-B which were clinically acceptable [Table/Fig-5]. The SEG analysis demonstrated that majority of the results fell within "no-risk" zone (risk score 0 to 0.5; 90.42%) [Table/Fig-6]. There was no occurrence of adverse event during study.



**[Table/Fig-5]:** Parkes-Consensus Error Grid analysis of EXIMO™ measurements. X axis denotes: reference glucose (mg/dl) Y axis denotes: test device glucose (mg/dl)



**[Table/Fig-6]:** Surveillance Error Grid analysis indicates risk levels of measurement errors.


**Subject questionnaires:** More than 95% of patients were strongly agree/agree with the questionnaire with respect to use of instrument, meter display, result understanding and kind of procedure after error displayed by the meter. However, approximately 90% of population

agreed with understanding of reference guide or instructions. [Table/Fig-7] depicts results of the ease-of-use subject questionnaires.

### DISCUSSION

The accuracy of BGMS is becoming increasingly important. Accurate BGMS eliminate adverse clinical and economic consequences of erroneous glucose measurement results [9]. Schnell O et al., observed reduction of BGMS errors from 20% to 15% resulted into considerable cost saving (€1.02 million and €6.03 million) due to reduction in adverse clinical consequences (1% in severe hypoglycaemia, 0.14% in A1C and 0.18% in myocardial infarction) [16].

It is critical that BGMS perform well in the hands of the intended users (people with diabetes and healthcare professionals). Recently, Hasslacher C et al., found that only fewer than half of the current BGMS fulfil accuracy requirements according to the ISO accuracy limits in a clinical setting [17]. Moreover, several studies evaluated performance of BGMS in which an experienced/trained healthcare professional performed the blood sampling [18]. Hence, the results of this study reflect mainly the technical performance of the devices. Errors (caused by patients) which are likely to be experienced in routine use may not be encountered in such studies [19]. In our study, enrolled patients themselves performed fingertip blood glucose measurement using the BGMS without any additional training (other than the user manual) to learn self-estimation of the blood glucose using the BGMS. Hence, the design of our study allowed occurrence of potential errors from all sources. Despite of this fact, the results of the study demonstrated that 95.82% of the measured glucose values fell within  $\pm 15$  mg/dl or 15% of the reference method value for glucose concentration  $< 100$  mg/dl and  $\geq 100$  mg/dl, respectively. Moreover, the CEG analysis assigns the error of BGMS measurement to 1 of 5 increasing clinical risk categories i.e., Results in Zone A indicates no effects of erroneous measurement on clinical action whereas results in Zone B indicates little to no effects on clinical action [14]. In the present study, all the measurements fell either in Zone A (99.47%) or Zone B (0.53%). However, it should be noted that CEG analysis does not take into account the advancement in diabetes therapy [20]. Hence, we further performed SEG analysis which has been developed as a result of joint effort of various medical societies and authorities (Diabetes Technology Society, Food and Drug Administration, American Diabetes Association, the Endocrine Society, and the Association for the Advancement of Medical Instrumentation, as well as representatives of academia, industry and government) [15]. The SEG analysis is suitable for both type 1 and type 2 diabetes patients. It displays clinical risks on a continuous colour-coded scale and allows greater precision in quantifying low risk [15]. In our study,



**[Table/Fig-7]:** Ease of use questionnaire for the use of EXIMO™ blood glucose monitoring system.

90.42% results fell in “No risk” zone, 9.05% results fell in “Slight, lower risk” zone and only 0.49% results fell in “Slight, higher risk” zone. Moreover, majority of the enrolled patients felt that EXIMO™ BGMS was easy to use. Currently, several BGMS are available in the market i.e., Contour Next USB (CNU; Bayer Consumer Care, Basel, Switzerland), FreeStyle InsuLinx (FIL; Abbott, Ludwigshafen, Germany), and OneTouch Verio IQ (OT; LifeScan, High Wycombe, UK) which utilise enzymatic method in their test strips (FAD-GDH) [20,21]. Bedini JL et al., compared 3 BGMS viz. CNU, FIL and OT for Blood glucose level between reference value and meter value. Their results by CEG and SEG analyses suggest a high accuracy of the CNU compared to other 2 BGMS. For CEG analysis, 100%, 98.80% and 99.30% for CNU, FIL and OT BGMS fall into Zone A i.e., “no effect on clinical action” respectively. While, 97.04% of measurements with the FIL BGMS were within the “no risk” zone of SEG analysis [21]. In contrast, EXIMO™ fell in Zone A with 99.47% and 0.53% (Zone B) of CEG analysis and 99.47% fall into “No risk” and “Slight lower risk” zone in SEG analysis. Therefore, EXIMO™ BGMS showed similar results with other comparable BGMS.

Consequently, the results of the study assure that the intended users (healthcare professionals and patients) of the BGMS can acquire accurate blood glucose measurements in real-life settings which may guide treating physician for deciding (diabetes) treatment strategy.

## LIMITATION

The limitation of the study includes probability of skin infections. In this study, we compared venous blood in reference laboratory method rather than fresh capillary whole blood samples. In addition, the glucose measurement by the BGMS was not performed in duplicate.

## CONCLUSION

We conclude that the compliance of EXIMO™ with tighter criteria of ISO 15197:2013 in this post-marketing study ensures performance of the system in the hands of untrained intended users in clinical settings.

**Conflict of interest:** Dr. Ashok Thakkar and Dr. Pankaj Kothavade are the employees of Meril Life Sciences Private Limited, Gujarat, India and all other authors have no conflict of interest.

## REFERENCES

- [1] Franciosi M, Lucisano G, Pellegrini F, Cantarello A, Consoli A, Cucco L, et al. ROSES: role of self-monitoring of blood glucose and intensive education in patients with type 2 diabetes not receiving insulin. A pilot randomized clinical trial. *Diabet Med.* 2011;28(7):789-96.
- [2] Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, et al. A structured self-monitoring of blood glucose approach in type 2 diabetes encourages more frequent, intensive, and effective physician interventions: results from the STeP study. *Diabetes Technol Ther.* 2011;13(8):797-802.
- [3] Fera T, Bluml BM, Ellis WM. Diabetes Ten City Challenge: final economic and clinical results. *J Am Pharm Assoc* (2003). 2009;49(3):383-91.
- [4] Karter AJ, Ackerson LM, Darbinian JA, D'Agostino RB, Ferrara A, Liu J, et al. Self-monitoring of blood glucose levels and glycaemic control: the Northern California Kaiser Permanente Diabetes registry. *Am J Med.* 2001;111(1):1-9.
- [5] Martin S, Schneider B, Heinemann L, Lodwig V, Kurth HJ, Kolb H, et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. *Diabetologia.* 2006;49(2):271-78.
- [6] AAE. AAE7 Self-Care Behaviors. *Diabetes Educ.* 2008;34(3):445-49.
- [7] Ginsberg BH. Practical use of self-monitoring of blood glucose data. *J Diabetes Sci Technol.* 2013;7(2):532-41.
- [8] Malanda UL, Bot SD, Nijpels G. Self-monitoring of blood glucose in noninsulin-using type 2 diabetic patients: it is time to face the evidence. *Diabetes Care.* 2013;36(1):176-78.
- [9] Klonoff DC, Prahald P. Performance of cleared blood glucose monitors. *J Diabetes Sci Technol.* 2015;9(4):895-910.
- [10] Freckmann G, Schmid C, Baumstark A, Rutschmann M, Haug C, Heinemann L. Analytical performance requirements for systems for self-monitoring of blood glucose with focus on system accuracy: relevant differences among ISO. 15197:2003, ISO 15197:2013, and current FDA recommendations. *J Diabetes Sci Technol.* 2015;9(4):885-94.
- [11] Zafar MN, Beden N, Leech D, Sygmund C, Ludwig R, Gorton L. Characterization of different FAD-dependent glucose dehydrogenases for possible use in glucose-based biosensors and biofuel cells. *Anal Bioanal Chem.* 2012;402(6):2069-77.
- [12] Guido F, Annette B, Nina J, Eva Z, Serge K, Jacques T et al. In vitro diagnostic test systems - Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. 2<sup>nd</sup> ed. 46 pages.
- [13] Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet.* 1986;1(8476):307-10.
- [14] Parkes JL, Slatin SL, Pardo S, Ginsberg BH. A new consensus error grid to evaluate the clinical significance of inaccuracies in the measurement of blood glucose. *Diabetes Care.* 2000;23(8):1143-48.
- [15] Klonoff DC, Lias C, Vigersky R, Clarke W, Parkes JL, Sacks DB, et al. The surveillance error grid. *J Diabetes Sci Technol.* 2014;8(4):658-72.
- [16] Schnell O, Hinzmann R, Kulzer B, Freckmann G, Erbach M, Lodwig V, et al. Assessing the analytical performance of systems for self-monitoring of blood glucose: concepts of performance evaluation and definition of metrological key terms. *J Diabetes Sci Technol.* 2013;7(6):1585-94.
- [17] Hasslacher C, Kulozik F, Platten I. Analytical performance of glucose monitoring systems at different blood glucose ranges and analysis of outliers in a clinical setting. *J Diabetes Sci Technol.* 2014;8(3):466-72.
- [18] Grant DA, Dunseath GJ, Bain SC, Luzio S. Postmarket approval surveillance of a low acquisition cost blood glucose monitoring system: assessment of the accuracy following ISO 15197:2013. *J Diabetes Sci Technol.* 2016;10(5):1195-96.
- [19] Krouwer JS. Analysis of the performance of the OneTouch SelectSimple blood glucose monitoring system: why ease of use studies need to be part of accuracy studies. *J Diabetes Sci Technol.* 2011;5(6):1610-11.
- [20] Bedini JL, Wallace JF, Pardo S, Petruschke T. Performance evaluation of three blood glucose monitoring systems using ISO 15197: 2013 accuracy criteria, consensus and surveillance error grid analyses, and insulin dosing error modeling in a hospital setting. *J Diabetes Sci Technol.* 2015;10(1):85-92.
- [21] Bedini JL, Wallace JF, Petruschke T, Pardo S. A multicenter performance evaluation of a blood glucose monitoring system in 21 leading hospitals in Spain. *J Diabetes Sci Technol.* 2016;10(1):93-100.

### PARTICULARS OF CONTRIBUTORS:

1. Consultant, Department of Gynaecologist and Obstetrician, Bombay Maternity and Surgical Hospital, Surat, Gujarat, India.
2. Professor, Department of Cardiology, Pariyaram Medical College, Kannur, Kerala, India.
3. Senior Physical Therapist, Department of Physiotherapy, Manish Therapy Services, Texas, USA.
4. Medical Writer, Department of Clinical Research, Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India.
5. Head, Department of Clinical Research, Meril Life Sciences Pvt. Ltd., Vapi, Valsad, India.

### NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Ashokkumar Suryakant Thakkar,  
Survey No.135/139, Bilakhia House, Muktanand Marg, Vapi-396191, Gujarat, India.  
E-mail: ashok.thakkar@merillife.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: **Jan 07, 2017**

Date of Peer Review: **Feb 11, 2017**

Date of Acceptance: **Apr 03, 2017**

Date of Publishing: **May 01, 2017**